MetaCap

Henry Schein (HSIC) vs Illumina (ILMN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Illumina (ILMN) has outperformed Henry Schein (HSIC) over the past year, gaining 55.7% versus a gain of 13.8%. Over five years, HSIC leads with a +13.4% price change compared with -46.4% for ILMN. Illumina is the larger company by market cap ($29.15 billion vs $9.23 billion), about 3.2 times the size, while Henry Schein is growing revenue faster (+4.0% vs -0.7%).

On valuation, Henry Schein trades at a lower forward P/E (13.9x vs 31.2x for Illumina). Illumina converts more of its revenue into profit, with a net margin of 19.6% versus 3.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HSIC+13.79%ILMN+55.69%
+144%+65%-15%
Nov 21, 20251 yearNov 20, 2026
HSIC+9.69%ILMN-47.75%
+25%-30%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HSIC versus ILMN key metrics
MetricHSICILMN
Share price$83.52$192.82
Market cap$9.23B$29.15B
1-day change-1.51%-3.90%
YTD return+10.51%+47.01%
1-year return+13.79%+55.69%
5-year return+13.42%-46.40%
P/E ratio (TTM)22.8833.19
Forward P/E13.9131.19
EPS (TTM)$3.65$5.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.18B$4.34B
Revenue growth (YoY)+4.03%-0.66%
Net income (latest FY)$398.00M$850.00M
Gross margin31.14%66.08%
Operating margin4.95%18.58%
Net margin3.02%19.57%
52-week high$92.18$309.35
52-week low$68.70$112.65
Distance from 52-week high-9.39%-37.67%
Analyst consensusbuybuy
Avg. price target upside+15.98%+35.59%
Average volume1.33M2.82M
Shares outstanding110.54M151.20M
Employees25,0008,600
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Illumina is about 3.2 times larger than Henry Schein by market value ($29.15B vs $9.23B).
  • ILMN has outperformed HSIC by 41.9 percentage points over the past year.
  • Illumina trades at a higher earnings multiple (33.2x vs 22.9x trailing P/E).
  • Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus 3.0 cents for Henry Schein.

About Henry Schein

HSIC stock →

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide.

Health Care · Medical Specialities · 25,000 employees

About Illumina

ILMN stock →

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Health Care · Medical Specialities · 8,600 employees

HSIC vs ILMN FAQ

Which is bigger, Henry Schein or Illumina?

Illumina (ILMN) is larger, with a market capitalization of $29.15B compared with $9.23B for Henry Schein (HSIC).

Which stock has performed better over the past year, HSIC or ILMN?

ILMN returned +55.69% over the past 12 months, compared with +13.79% for HSIC (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, HSIC or ILMN?

HSIC has the lower trailing P/E at 22.9, versus 33.2 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Henry Schein and Illumina in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons